Cancer therapie with dSLIM

 

In its use of the immunomodulator and TLR9 agonist  dSLIM, MOLOGEN is implementing a very promising approach to the treatment of cancer that is based on broad-based activation of the immune system.

In a healthy organism, sick cells are identified and destroyed by the immune system. When a person is suffering from cancer, this defence system does not work any more, i.e. the body develops "tolerance" to the tumor cells. The cancer cells are no longer recognized by the immune system, so that no defence mechanism can be triggered. As a result, the cancer cells are able to multiply uncontrolled.

One of the biggest hopes in cancer research is based on finding a way to overcome this tolerance. Various antigens that occur on the surface of tumor cells play a key role here. When healthy cells mutate into cancer cells, what are known as tumor-associated antigens (TAA) are formed at the same time that are then presented on the cell membrane of the tumor cell. So if the immune system can be influenced specifically in such a way that it recognises these antigens, there is a good chance of an improvement in health or even healing of the disease ( Mode of action) 

 

There are high expectations in the immune treatment field of substances that bond to specific receptors, which are known as toll-like receptors ( TLR). These receptors are part of the innate defence system. They have the ability to facilitate recognition of tumor-associated antigens by activating the immune system. Research projects lasting many years have demonstrated that the toll-like receptor 9 (TLR9) plays a particularly crucial role in combatting cancer. Substances that activate TLR9 are called TLR9 agonists and are the focal point of global research and development activities.

 

For further information please contact:

Arlett Killat

 

MOLOGEN®, MIDGE® and dSLIM® are registered trademarks of MOLOGEN AG